Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of ...
Background Guidelines strongly recommend reperfusion therapy, including thrombolysis and percutaneous coronary intervention, ...
Niagen Bioscience, Inc. , the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind ...
Background Acute decompensated heart failure (ADHF) with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated.
Background: Observational studies have suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation ...
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
Penumbra, Inc. (NYSE: PEN) announced additional results of the ground-breaking STORM-PE randomized controlled trial (RCT), ...
Background Pain and fatigue are among the most debilitating symptoms of systemic sclerosis (SSc), severely impairing quality ...
Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer A key but often overlooked question in oncology clinical ...
A large study has found it makes no difference to eczema symptoms if people bathe daily or weekly. Researchers said the ...
Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback